The other Ozempic
With the end of the patent expected, pharmaceutical companies are already mobilizing to carry out tests. Sometimes, shortly after the end of exclusivity, a new medicine is already authorized to circulate.
Everything depends, of course, on approval by the competent bodies based on the analysis of studies that prove the safety and effectiveness of the product.
In mid-April, the Brazilian company Biomm signed an exclusive agreement with the Indian biopharmaceutical company Biocon for the licensing, commercialization and distribution of the biological drug semaglutide in the country.
The import, distribution and commercialization of the substance are still subject to the expiration of the patent, approval of registration with Anvisa and publication of the price by CMED (Chamber of Medicines Market Regulation).
Outside Brazil, Chinese pharmaceutical company Hangzhou Jiuyuan Gene Engineering also developed a biosimilar version of Ozempic. At the beginning of April, the company said it had requested approval of the drug in the country of origin, with the purpose of glycemic control in people with type 2 diabetes.
